Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mannose-Binding Lectin and Risk of Cardiovascular Events and Mortality in Type 2 Diabetes: A Danish Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of Glucose Level on Micro- and Macrovascular Disease in the General Population: A Mendelian Randomization Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lactation Duration and Long-term Risk for Incident Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Left ventricular myocardial crypts: morphological patterns and prognostic implications

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Left ventricular trabeculation and major adverse cardiovascular events: the Copenhagen General Population Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • DAPA-HF Investigators and Committees
  • Gunnar Hilmar Gislason (Member of study group)
  • Morten Schou (Member of study group)
View graph of relations

OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).

RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.

RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.

CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.

Original languageEnglish
JournalDiabetes Care
Volume43
Issue number11
Pages (from-to)2878-2881
Number of pages4
ISSN1935-5548
DOIs
Publication statusPublished - Nov 2020

ID: 61265145